Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Berry-Kravis

Showing results (131-140 of 265) with videos related to

Pageof 27
Sort By:
Journal of Developmental and Behavioral Pediatrics : JDBP|February 20, 2020
Neurodevelopmental Characterization of Young Children Diagnosed with Niemann-Pick Disease, Type C1Audrey Thurm, Colby Chlebowski, Lisa Joseph, et al.
Therapeutic Advances in Rare Disease|September 19, 2024
A roadmap for SHANK3-related Epilepsy Research: recommendations from the 2023 strategic planning workshopMargaret C Savage, Geraldine Bliss, Joseph D Buxbaum, et al.
Scientific Reports|November 20, 2018
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescentsRandi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, et al.
Journal of Neurodevelopmental Disorders|March 25, 2020
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validityLeonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, et al.
Journal of Neurodevelopmental Disorders|February 9, 2016
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension studyDonald B Bailey, Elizabeth Berry-Kravis, Anne Wheeler, et al.
Journal of Neurodevelopmental Disorders|October 18, 2019
Vocabulary comprehension in adults with fragile X syndrome (FXS)Anne Hoffmann, Sue Ellen Krause, Joanne Wuu, et al.
Brain Sciences|October 23, 2021
Symptoms of Autism Spectrum Disorder in Individuals with Down SyndromeAmanda Dimachkie Nunnally, Vivian Nguyen, Claudine Anglo, et al.
Brain Sciences|September 16, 2020
Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial AnalysisSkylar Luu, Haley Province, Elizabeth Berry-Kravis, et al.
Cerebellum (London, England)|October 29, 2020
The Effects of Dual Task Cognitive Interference and Fast-Paced Walking on Gait, Turns, and Falls in Men and Women with FXTASJoan A O'Keefe, Joseph Guan, Erin Robertson, et al.
Journal of Neurodevelopmental Disorders|June 16, 2017
Updated report on tools to measure outcomes of clinical trials in fragile X syndromeDejan B Budimirovic, Elizabeth Berry-Kravis, Craig A Erickson, et al.
Pageof 27

Showing results (131-140 of 265) with videos related to

Sort By:
Pageof 27
Journal of Developmental and Behavioral Pediatrics : JDBP|February 20, 2020
Neurodevelopmental Characterization of Young Children Diagnosed with Niemann-Pick Disease, Type C1Audrey Thurm, Colby Chlebowski, Lisa Joseph, et al.
Therapeutic Advances in Rare Disease|September 19, 2024
A roadmap for SHANK3-related Epilepsy Research: recommendations from the 2023 strategic planning workshopMargaret C Savage, Geraldine Bliss, Joseph D Buxbaum, et al.
Scientific Reports|November 20, 2018
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescentsRandi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, et al.
Journal of Neurodevelopmental Disorders|March 25, 2020
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validityLeonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, et al.
Journal of Neurodevelopmental Disorders|February 9, 2016
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension studyDonald B Bailey, Elizabeth Berry-Kravis, Anne Wheeler, et al.
Journal of Neurodevelopmental Disorders|October 18, 2019
Vocabulary comprehension in adults with fragile X syndrome (FXS)Anne Hoffmann, Sue Ellen Krause, Joanne Wuu, et al.
Brain Sciences|October 23, 2021
Symptoms of Autism Spectrum Disorder in Individuals with Down SyndromeAmanda Dimachkie Nunnally, Vivian Nguyen, Claudine Anglo, et al.
Brain Sciences|September 16, 2020
Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial AnalysisSkylar Luu, Haley Province, Elizabeth Berry-Kravis, et al.
Cerebellum (London, England)|October 29, 2020
The Effects of Dual Task Cognitive Interference and Fast-Paced Walking on Gait, Turns, and Falls in Men and Women with FXTASJoan A O'Keefe, Joseph Guan, Erin Robertson, et al.
Journal of Neurodevelopmental Disorders|June 16, 2017
Updated report on tools to measure outcomes of clinical trials in fragile X syndromeDejan B Budimirovic, Elizabeth Berry-Kravis, Craig A Erickson, et al.
Pageof 27